Biomarkers of bone turnover in oncology: applications in diagnosis and treatment

Bibliography

• Seeman E, Delmas P. Bone quality – the material and structural basis of bone strength and fragility. New Engl J Med 2006;354:2250-61
   PubMed Web of Science ®Google Scholar
• Mundy GR. Structure and physiology of the normal skeleton. In: Rubens RD, Mundy GR, editors, Cancer and the skeleton. Martin Dunitz, London; 2000. p. 1-19
   Google Scholar
• Tanaka S, Miyazaki T, Fukuda A, Molecular mechanism of the life and death of the osteoclast. Ann NY Acad Sci 2006;1068:180-6
   PubMed Web of Science ®Google Scholar
• Krane SM. Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med 2005;201:841-3
   PubMed Web of Science ®Google Scholar
• Take I, Takahash N, Kurihara S. Molecules which are involved in osteoclastic bone resorption: from the aspect of targets of treatment for osteoporosis. Clin Calcium 2005;15:741-6
   PubMedGoogle Scholar
• Katagiri T, Fukuda T. Molecular mechanisms of bone formation and bone-forming factors. Clin Calcium 2005;15:17-22
   PubMedGoogle Scholar
• Wright HL, McCarthy HS, Middleton J, Marshall MJ. RANK, RANKL and osteoprotogerin in bone biology and disease. Curr Rev Musculoskelet Med 2009;2:56-64
   PubMedGoogle Scholar
• Lacey DL, Timms E, Tan HL, Osteoprotogerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76
   PubMed Web of Science ®Google Scholar
• Martin TJ, Danks JA, Henderson MA. Parathyroid hormone-related protein and bone metastases. In Textbook of Bone Metastases, Jasmin C, Coleman RE, Coia LR, Capanna R, Saillant G, editors. New York: John Wiley and Sons; 2005
   Google Scholar
• Roodman DG, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008;34:92-101
   PubMed Web of Science ®Google Scholar
• Bartsch R, Steger GG. Role of denosumab in breast cancer. Expert Opin Biol Ther 2009; 9:1225-33
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94
   PubMed Web of Science ®Google Scholar
• Kingsley LA, Fournier PJR, Chirgwin, Molecular biology of bone metastases. Mol Cancer Ther 2007;6:2609-17
   PubMed Web of Science ®Google Scholar
• Guise TA, Mohammad KS, Clines G, Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213-16
   PubMed Web of Science ®Google Scholar
• Brown JE, Chow E. Bone biomarkers in research and clinical practice. In bone metastases: a translational and clinical approach. In: Kardamakis D, Vassiliou V, Chow E, editors. Berlin: Springer; 2009. p. 93-116
   Google Scholar
• Zhang XH, Wang Q, Gerald W, Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78
   PubMed Web of Science ®Google Scholar
• Rucci N, Recchia I, Angelucci A, Inhibition of protein kinase c-Src reduces the incidence of brast cancer metastases and increases survival in mice. J Pharmacol Exp Ther 2006;318:161-72
   PubMed Web of Science ®Google Scholar
• Mourskaia A, Dong Z, Ng S, Transforming growth factor-beta 1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 2009;28:1005-15
   PubMed Web of Science ®Google Scholar
• Kang Y, He W, Tulley S, Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2006;102:13909-14
   Web of Science ®Google Scholar
• Coleman RE, Body JJ, Gralow JR, Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 2008;34:(Suppl 1):S31-42
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez Toriz N, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:818-20
   PubMedGoogle Scholar
• Saad F, Hussain A. Bisphosphonates in the management of metastatic bone disease. In: Kardamakis D, Vassiliou V, Chow E, editors, Bone metastases: a translational and clinical approach. Berlin: Springer; 2009. p. 195-231
   Google Scholar
• Ebeling PR. Potential candidates for bone turnover markers – N-telopeptide cross-links of type I collagen (NTX). In: Eastell R, Baumann M, Hoyle NR, Wieczorek L, editors, Bone markers: biochemical and clinical perspectives. Martin Dunitz, London; 2001. p. 28-38
   Google Scholar
• Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998;34:252-9
   PubMed Web of Science ®Google Scholar
• Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev 1996;17:333-68
   PubMed Web of Science ®Google Scholar
• Coleman R, Brown J, Terpos E, Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34:629-39
   PubMed Web of Science ®Google Scholar
• Garnero P, Borel O, Gineyts E, Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 2006;38:300-9
   PubMed Web of Science ®Google Scholar
• Viguet-Carrin S, Roux JP, Arlot ME, Contribution of advanced glycation end product pentosidine and of maturation of type I collagen to compressed biomechanical properties of human lumbar vertebrae. Bone 2006;39:1073-9
   PubMed Web of Science ®Google Scholar
• Aruga A, Kolzumi M, Hotta R, Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 1997;76:760-4
   PubMed Web of Science ®Google Scholar
• Leary TE. C-telopeptides. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L, eds, Bone Markers: biochemical and clinical perspectives. Martin Dunitz, London; 2001. p. 39-48
   Google Scholar
• Jakob C, Zavrski I, Heider U. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 2003;9:3047-51
   PubMed Web of Science ®Google Scholar
• Demers LM, Costa L, Chinchilli VM, Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-94
   PubMed Web of Science ®Google Scholar
• Vinholes JJ, Guo C-Y, Purohit OP, Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996;73:1089-95
   PubMed Web of Science ®Google Scholar
• Fedarko NS, Jain A, Karadag A, Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6
   PubMed Web of Science ®Google Scholar
• Diel IJ, Solomayer EF, Siebel MJ, Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999;5:3914-9
   PubMed Web of Science ®Google Scholar
• Papotti M, Kalebic T, Volante M. Bone sialoprotein is predictive of bone metastases in respectable non small cell lung cancer. A retrospective case control study. J Clin Oncol 2006;24:4818-23
   PubMed Web of Science ®Google Scholar
• Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrin Metab 2003;88:5059-75
   PubMed Web of Science ®Google Scholar
• Woitge HW, Pecherstorfer M, Horn E, Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 2001;84:344-51
   PubMed Web of Science ®Google Scholar
• Jung K, Lein M, Stephan C. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111:783-91
   PubMed Web of Science ®Google Scholar
• Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 2003;23:1027-9
   PubMed Web of Science ®Google Scholar
• Halleen JM, Ylipahkala H, Alatalo SL, Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 2002;71:20-5
   PubMed Web of Science ®Google Scholar
• Korpela J, Tiitinen SL, Hiekkanen H, Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 2006;26:3127-32
   PubMed Web of Science ®Google Scholar
• Chung YC, Ku CH, Chao TY, Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 2006;15:424-8
   PubMed Web of Science ®Google Scholar
• Ozu C, Nakashima J, Horiguchi Y, Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, lkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 2008;15:419-22
   PubMed Web of Science ®Google Scholar
• Salminen EK, Kallioinen MJ, Ala-Houhala MA, Survival markers related to bone metastases. Anticancer Res 2006;26:4879-84
   PubMed Web of Science ®Google Scholar
• Hegele A, Wahl HG, Varga Z, Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 2007;99:330-4
   PubMed Web of Science ®Google Scholar
• Jung K, Lein M, Ringsdorf M, Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 2006;176:1326-31
   PubMed Web of Science ®Google Scholar
• Terpos E, Szydlo R, Apperley JF, Soluble receptor activator of nucleay factor kappaB ligand-osteoprotogerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064-9
   PubMed Web of Science ®Google Scholar
• Rogers A, Eastell R. Circulating osteoprotogerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrin Metab 2005;90:6323-31
   PubMed Web of Science ®Google Scholar
• Brown JM, Vassella RM, Kostenuik PJ, Serum osteoprotogerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001;7:2977-83
   PubMed Web of Science ®Google Scholar
• Brandt J, Frederiksen JK, Jensen CH, The N- and C-terminal propeptides of human procollagen type 1 (P1NP and PICP): molecular heterogeneity and assay technology. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L, editors, Bone markers: biochemical and clinical perspectives. Martin Dunitz, London; 2001. p. 73-81
   Google Scholar
• Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Reviews 2005;19:125-42
   PubMed Web of Science ®Google Scholar
• Balcerzak M, Hamade E, Zhang L. The roles of annexins and alkaline phosphatase in mineralization process. Acta Biochim Pol 2003;50:1019-38
   PubMed Web of Science ®Google Scholar
• Demers LM. Bone-specific alkaline phosphatase. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L, eds, Bone markers: biochemical and clinical perspectives, Martin Dunitz, London; 2001. p. 49-64
   Google Scholar
• Gundberg CM. Osteocalcin. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L, editors, Bone markers: biochemical and clinical perspectives. Martin Dunitz, London; 2001. p. 65-72
   Google Scholar
• Ivaska KK, Kakonen S-M, Gerdhem P, Urinary osteocalcin as a marker of bone metabolism. Clin Chem 2005;51:618-28
   PubMed Web of Science ®Google Scholar
• Vinholes J, Coleman R, Lacombe D, Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organisation for Research and Treatment of Cancer. Br J Cancer 1999;80:221-8
   PubMed Web of Science ®Google Scholar
• Body JJ, Dumon JC, Gineyts E, Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997;75:408-12
   PubMed Web of Science ®Google Scholar
• Walls J, Assiri A, Howell A, Measurement of urinary collagen crosslinks indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 1999;80:1265-70
   PubMed Web of Science ®Google Scholar
• Garnero P, Buchs N, Zekri J. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000;82:858-64
   PubMed Web of Science ®Google Scholar
• Kanakis I, Nikolaou M, Pectasides D. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal 2004;34:827-32
   PubMed Web of Science ®Google Scholar
• Brown JE, Cook RJ, Major P, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69
   PubMed Web of Science ®Google Scholar
• Coleman RE, Major P, Lipton A, Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35
   PubMed Web of Science ®Google Scholar
• Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001;27:187-92
   PubMed Web of Science ®Google Scholar
• Koizumi M, Yonese J, Fukui I, The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001;87:348-51
   PubMed Web of Science ®Google Scholar
• Koizumi M, Maeda H, Yoshimura K, Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer 1997;75:1601-4
   PubMed Web of Science ®Google Scholar
• Coleman RE, Mashiter G, Fogelman I, Osteocalcin: a marker of metastatic bone disease.. Eur J Cancer 1988;24:1211-17
   Web of Science ®Google Scholar
• Berruti A, Panero A, Angelli A, Different mechanisms underlying bone collagen resorption in patients with bone metastases from prostate and breast cancer. Br J Cancer 1996;73:1581-87
   PubMedGoogle Scholar
• Berruti A, Torta M, Piovesan A, Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res 1995;15:2871-76
   PubMed Web of Science ®Google Scholar
• Costa L, Demers LM, Gouveia A, Biochemical markers of bone turnover correlate with the extent of metastatic bone disease. Proc ASCO Abstract 1999;18:2375
   Google Scholar
• Chao TY, Yu JC, Ku CH, Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 2005;11:544-50
   PubMed Web of Science ®Google Scholar
• Voorzanger-Rousselot N, Juillet F, Mareau E, Association of 12 serum biocehmical markers of angiogenesis, tunmour invasion and bone turnover with bone metastases from breast cancer: a cross-sectional and longitudinal evaluation. Br J Cancer 2006;95:506-14
   PubMed Web of Science ®Google Scholar
• Pollmann D, Siepmann S, Geppert R, The amino-terminal propeptide (P1NP) of type I collagen is a clinically valid indicator of one turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 2007;27:1853-62
   PubMed Web of Science ®Google Scholar
• Luftner D, Jozereau D, Schildhauer S, P1NP as serum marker of metastatic spread to bone in breast cancer patients. Anticancer Res 2005;25:1491-9
   PubMed Web of Science ®Google Scholar
• Koopmans N, de Jong IL, Breeuwsma AJ, van der Veer E. Serum bone turnover markers (P1NP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007;178:849-53
   PubMed Web of Science ®Google Scholar
• Klepzig M, Jonas D, Oremek BM. Procollagen type I aminoterminal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res 2009;29:671-3
   PubMed Web of Science ®Google Scholar
• Lein M, Wirth M, Miller K, Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007;52:1381-7
   PubMed Web of Science ®Google Scholar
• Izumi M, Nakanishi Y, Takayama K, Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung cacinoma. Cancer 2001;91:1487-93
   PubMed Web of Science ®Google Scholar
• Ebert W, Muley T, Herb KP, Comparison of bone scintigraphy with one markers in the diagnosis of bone metastases in lung carcinoma patients. Anticancer Res 2004;24:3193-201
   PubMed Web of Science ®Google Scholar
• Tzelepi V, Tsamandas AC, Vassiliki Z, Bone anatomy, physiology and function. In: Kardamakis D, Vassiliou V, Chow E, editors. Bone metastases: a translational and clinical approach. Berlin: Springer; 2009. p. 3-29
   Google Scholar
• Lipton A, Demers L, Curley E, Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-6
   PubMed Web of Science ®Google Scholar
• Ali SM, Demers LM, Leitzel K, Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004;15:455-9
   PubMed Web of Science ®Google Scholar
• Abildgaard N, Brixen K, Kristensen JE. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematology 2003;120:235-42
   PubMed Web of Science ®Google Scholar
• Brown JE, Thomson C, Ellis S, Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-7
   PubMed Web of Science ®Google Scholar
• Brown JE, Lipton A, Cook RJ, Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients with bone metastases from renal cell carcinoma [abstract16016]. J Clin Oncol 2009;27(Suppl)
   Google Scholar
• Hirsch V, Major P, Lipton A, Zoeldronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:22-36
   Google Scholar
• Menssen HD, Sakalova A, Fontana A, Effects of long term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353-9
   PubMed Web of Science ®Google Scholar
• Brasso K, Christensen IJ, Johansen JS. Prognostic value of P1NP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66:503-13
   PubMed Web of Science ®Google Scholar
• Brown JE, McCloskey EV, Dewar JA, The use of bone markers in six-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 2007;81:341-51
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon G, Kaminski M, Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a double-blind, multicentre, comparative trial. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Vinholes JJ, Purohit OP, Abbey ME, Relationship between biochemical and symptomatic response in a double blind trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243-50
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook RJ, Major P, Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclasts activity. Oncologist 2007;12:1035-43
   PubMed Web of Science ®Google Scholar
• Lipton A, Cook R, Saad F, Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumours and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201
   PubMed Web of Science ®Google Scholar
• Brown JE, Ellis S, Gutcher S, Turner L. The bone resorption marker NTX is strongly correlated with skeletal events in metastatic bone disease and is influenced by dose escalation of clodronate. Am Soc Clin Oncol 2002;21:385a
   Google Scholar
• US National Institutes of Health. Clinical trials: randomized study of bone marker-directed schedule versus standard schedule of zoledronic acid in patients with advanced breast cancer metastatic to the bone. Available from: http://www.cancer.gov/clinicaltrials/NCRI-BISMATK. [Accessed 31 October 2007]
   Google Scholar
• UK Clinical Research Network: Portfolio Database. Cost-effective use of BISphosphonates in metastatic bone disease – a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule – the BISMARK trial. Available from: http://pfsearch.ukcrn.org.uk/StudyDetail.aspx?TopicID=1&StudyID=1737. [Accessed 31 October 2007]
   Google Scholar
• Clemons M, Dranitsaris G, Ooi W, Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006;24:4895-900
   PubMed Web of Science ®Google Scholar
• Simmons C, Broom RJ, Cole DEC, Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonates therapy in patients with metastatic breast cancer. Support Cancer Ther 2007;4:182-7
   PubMedGoogle Scholar
• Clemons M, Dranitsaris G, Ooi W, A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonates (BP) therapy. Breast Cancer Res Treat 2008;108:79-85
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cacer or other neoplasm after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
   PubMed Web of Science ®Google Scholar
• Fizazi K, Bosserman L, Gao G, Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009;182:509-15
   PubMed Web of Science ®Google Scholar
• Body JJ, Lipton A, Gralow J, Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J, Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371-9
   PubMed Web of Science ®Google Scholar
• Terpos E, Heath DJ, Rahemtulla A, Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006;135:688-92
   PubMed Web of Science ®Google Scholar
• Stoch SA, Zajic S, Stone J, Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomised, placebo-controlled phase I studies. Clin Pharmacol Ther 2009;86:175-82
   PubMed Web of Science ®Google Scholar
• Garnero P, Gineyts E, Riou JP, Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780-5
   PubMed Web of Science ®Google Scholar
• Sassi ML, Eriksen H, Risteli L, Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000;26:367-73
   PubMed Web of Science ®Google Scholar
• Robins SP, Woitge H, Hesley R, Direct enzyme linked-immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Min Res 1994;9:1643-9
   PubMed Web of Science ®Google Scholar
• Seyedin SM, Kung VT, Daniloff YN, Immunoassay for urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 1993;8:635-41
   PubMed Web of Science ®Google Scholar
• Gomez B, Ardakani S, Evans B, Monoclonal antibodies assay for free urinary pyridinium cross-links. Clin Chem 1996;42:1168-75
   PubMed Web of Science ®Google Scholar